Insulet Corporation (NASDAQ:PODD) announced additional promising data from first feasibility study


Insulet Corporation (NASDAQ:PODD) announced additional promising data from the first feasibility study of the Omnipod®Horizon™ Automated Glucose Control System (Omnipod Horizon) hybrid closed-loop system. Initial results presented earlier this year demonstrated Insulet’s personalized model predictive control (MPC) algorithm performed well, was safe during the day and night for adults with type 1 diabetes, and was very effective at night with minimal hypoglycemia and excellent fasting glucose.1 New data revealed today at the American Diabetes Association (ADA) 77th Scientific Sessions in San Diego demonstrated pediatric and adolescent populations experienced positive results consistent with the performance in the adult population, reinforcing Insulet’s expectation of the many future benefits of the Omnipod Horizon. The 36-hour study included a modified version of Insulet’s Omnipod System, a Dexcom®continuous glucose sensor, and Insulet’s personalized MPC algorithm with announced meals ranging from 30-90 grams of carbohydrates and limited physical activity. Overall, the study included 34 adults, 12 adolescents and 12 pediatric patients with type 1 diabetes.1-3Key findings in the pediatric and adolescent patients included greater than 70% of time spent in the target blood glucose range overall and approximately 85% or greater time in the target range overnight. These initial results indicate that the algorithm performance can address the unique challenges faced by pediatric populations with high insulin sensitivity and adolescents who tend to be insulin resistant.

On Monday Insulet Corporation (NASDAQ:PODD) share price closed at $43.84. Company net profit margin stands at -6.80% whereas its return on equity (ROE) is -48.10%. Insulet Corporation (NASDAQ:PODD) is -9.10% away from its 52 week high and its 52 week range is $27.62 – $48.23.

Myriad Genetics, Inc. (NASDAQ:MYGN) unveiled positive data pertaining to its BRACAnalysis CDx test. This breast cancer (BRAC) assay successfully identified patients with HER2- metastatic breast cancer in the OlympiAD trial who responded better to treatment with olaparib than standard chemotherapy. BRACAnalysis CDx is the laboratory test to identify germ line BRCA1 and BRCA2 mutations and is intended to inform patients related to the poly ADP ribose polymerase (PARP) inhibitors which are Lynparza (olaparib) and Zejula (niraparib). The test was developed in collaboration with AstraZeneca back in 2007. Notably, over the last three months, Myriad Genetics has been trading above the Zacks categorized Medical – Biomedical and Genetics industry. As per the latest share price movement, the company has gained 6.7% in this period, which is way better than the 6% decline of the broader industry.

Myriad Genetics, Inc. (NASDAQ:MYGN) traded 1.02 Million shares and its share price moved up 1.18% to close at $22.24. Company has 0.20% insider ownership. Myriad Genetics, Inc. (NASDAQ:MYGN) quarterly performance is 13.07% while its year to date (YTD) performance is 33.41%.

On Monday shares of Glaukos Corporation (NYSE:GKOS) ended up at $39.22. This year Company’s Earnings per Share (EPS) growth is 105.80% and next year’s EPS growth is 156.40%. Glaukos Corporation (NYSE:GKOS) weekly performance is 4.03%.

Danaos Corporation (NYSE:DAC) moved up 3.70% to close at $1.40 on 12 June. Its return on assets (ROA) is -11.60% while return on investment (ROI) is -7.10%. Danaos Corporation (NYSE:DAC) price to sales (P/S) ratio is 0.34.


Please enter your comment!
Please enter your name here